Abstract
Aldose Reductase (ALR2) is defined as the first enzyme of the “polyol pathway”. As such, ALR2 would convert glucose to sorbitol through an NADPH dependent reaction. Considered a promoter of osmotic imbalance under hyperglycemic conditions, the enzyme has been under intense investigation as a critical target to prevent and control diabetic complications through the inhibition of its activity. Further characterization of ALR2 suggests its participation in cell detoxification mechanisms through the reduction of toxic aldehydes. Moreover, intriguing is the apparent involvement of the enzyme in the signalling machinery of inflammatory cell response. Here, the structural and functional assessment of ALR2 as an aldose/aldehyde reducing enzyme, and its involvement in various aspects of cell function from sugar metabolism to redox homeostasis and cell signaling are presented.
Keywords: Aldose reductase, polyol pathway
Current Medicinal Chemistry
Title: From a Dull Enzyme to Something Else: Facts and Perspectives Regarding Aldose Reductase
Volume: 15 Issue: 15
Author(s): A. Del Corso, M. Cappiello and U. Mura
Affiliation:
Keywords: Aldose reductase, polyol pathway
Abstract: Aldose Reductase (ALR2) is defined as the first enzyme of the “polyol pathway”. As such, ALR2 would convert glucose to sorbitol through an NADPH dependent reaction. Considered a promoter of osmotic imbalance under hyperglycemic conditions, the enzyme has been under intense investigation as a critical target to prevent and control diabetic complications through the inhibition of its activity. Further characterization of ALR2 suggests its participation in cell detoxification mechanisms through the reduction of toxic aldehydes. Moreover, intriguing is the apparent involvement of the enzyme in the signalling machinery of inflammatory cell response. Here, the structural and functional assessment of ALR2 as an aldose/aldehyde reducing enzyme, and its involvement in various aspects of cell function from sugar metabolism to redox homeostasis and cell signaling are presented.
Export Options
About this article
Cite this article as:
Corso Del A., Cappiello M. and Mura U., From a Dull Enzyme to Something Else: Facts and Perspectives Regarding Aldose Reductase, Current Medicinal Chemistry 2008; 15 (15) . https://dx.doi.org/10.2174/092986708784638870
DOI https://dx.doi.org/10.2174/092986708784638870 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
Current advances in inherited cardiomyopathy
Describe in detail all novel advances in multimodality imaging related to inherited cardiomyopathy diagnosis and prognosis. Shed light to deeper phenotypic characterization. Acknowledge recent advances in genetics, genomics and precision medicineread more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Mechanistic Links Between Proteasome Activity, Aging and Agerelated Diseases
Current Genomics Editorial [Hot Topic: RNA Granules in Health and Disease (Guest Editor: Dra. Graciela L. Boccaccio)]
Current Chemical Biology Ketamine: New Indications for an Old Drug
Current Drug Targets Beneficial Effects of Dietary Supplements Against Mitochondrial Dysfunction and Apoptosis in Neurodegenerative Diseases
Current Pharmacogenomics and Personalized Medicine Immunophilins in Nervous System Degeneration and Regeneration
Current Topics in Medicinal Chemistry Targeting Exocytosis: Ins and Outs of the Modulation of Quantal Dopamine Release
CNS & Neurological Disorders - Drug Targets Inflammasome as a New Therapeutic Target for Diabetic Complications
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Immunopathology of Type 1 Diabetes and Immunomodulatory Effects of Stem Cells: A Narrative Review of the Literature
Endocrine, Metabolic & Immune Disorders - Drug Targets Colloidal Supramolecular Aggregates for Therapeutic Application in Neuromedicine
Current Medicinal Chemistry Mitochondrial Targeting for Development of Novel Drug Strategies in Brain Injury
Central Nervous System Agents in Medicinal Chemistry A Review on Electrocardiographic Changes in Diabetic Patients
Current Diabetes Reviews Imaging of Organ Metabolism in Obesity and Diabetes: Treatment Perspectives
Current Pharmaceutical Design Assessment of Glomerular and Tubular Function
Current Pediatric Reviews Nanoparticles for the Treatment of Wounds
Current Pharmaceutical Design FoxO1 Inhibitors: The Future Medicine for Metabolic Disorders?
Current Diabetes Reviews Histological and Direct Evidence for the Role of Complement in the Neuroinflammation of AD
Current Alzheimer Research Neurobiology of Depression and Novel Antidepressant Drug Targets
Current Pharmaceutical Design Current Clinical Applications of Botulinum Toxin
Current Pharmaceutical Design Nonfasting Hyperlipidemia and Cardiovascular Disease
Current Drug Targets Platelets and Platelet-Derived Microvesicles as Immune Effectors in Type 2 Diabetes
Current Vascular Pharmacology